• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Rises Sharply; Elbit Systems Shares Fall After Q1 Results

    5/28/24 2:34:02 PM ET
    $APDN
    $CALT
    $ESLT
    $INSM
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 250 points on Tuesday.

    The Dow traded down 0.69% to 38,798.34 while the NASDAQ rose 0.41% to 16,990.44. The S&P 500 also fell, dropping, 0.11% to 5,298.87.

    Check This Out: This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

    Leading and Lagging Sectors

    Information technology shares jumped by 1.5% on Tuesday.

    In trading on Tuesday, health care shares fell by 1.4%.

    Top Headline

    Shares of Elbit Systems Ltd. (NASDAQ:ESLT) fell around 2.5% on Tuesday after the company reported results for the first quarter.

    The company reported first-quarter FY24 revenue of $1.554 billion, beating the consensus of $1.463 billion. Adjusted EPS rose to $1.81 from $1.78 a year ago, beating the consensus of $1.35, according to data from Benzinga Pro.

    Equities Trading UP
                           

    • Insmed Incorporated (NASDAQ:INSM) shares shot up 109% to $45.90 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.
    • Shares of Calliditas Therapeutics AB (NASDAQ:CALT) got a boost, surging 73% to $37.84 after the company’s board recommended the acceptance of Asahi Kasei’s tender offer.
    • Pineapple Energy Inc. (NASDAQ:PEGY) shares were also up, gaining 74% to $0.3094 after the company on Friday announced its SUNation subsidiary signed a 1.95-megawatt project.

    Equities Trading DOWN

    • Applied DNA Sciences, Inc. (NASDAQ:APDN) shares dropped 69% to $0.6250 after the company reported the pricing of $12 million public offering.
    • Shares of Marpai, Inc.  (NASDAQ:MRAI) were down 53% to $0.9223 after the company announced its intention to withdraw from the Nasdaq hearings process.
    • Netcapital Inc. (NASDAQ:NCPL) was down, falling 25% to $0.1442 after the company announced that it entered into definitive agreement for the immediate exercise of $2.2 million of certain outstanding Series A-2 warrants.

    Also Check This Out: Top 5 Real Estate Stocks That Could Lead To Your Biggest Gains This Month

    Commodities

    In commodity news, oil traded up 2.6% to $79.70 while gold traded up 0.9% at $2,354.70.

    Silver traded up 5.2% to $32.07 on Tuesday, while copper rose 2.1% to $4.8525.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.60%, Germany's DAX slipped 0.52% and France's CAC 40 declined 0.92%. Spain's IBEX 35 Index fell 0.44%, while London's FTSE 100 declined 0.76%.

    German wholesale prices fell by 1.8% year-over-year in April compared to a revised 2.6% decline a month ago.

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan's Nikkei falling 0.11%, China's Composite Index declining 0.46%, Hong Kong's Hang Seng Index falling 0.03% and India's S&P BSE Sensex falling 0.2%.

    Producer prices in Malaysia rose by 1.9% year-over-year in April compared to a 1.6% increase in the earlier month.

    Economics

    • The S&P CoreLogic Case-Shiller home price index rose by 7.4% year-over-year in March versus 7.3% in the previous month.
    • The FHFA house price index rose by 0.1% in March, compared to market expectations of a 0.5% gain.
    • The Federal Reserve Bank of Dallas’ general business activity index for manufacturing in Texas fell to a reading of -19.4 in May, compared to -14.5 a month ago.

    Now Read This: How To Earn $500 A Month From Heico Stock Ahead Of Q2 Earnings

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $CALT
    $ESLT
    $INSM

    CompanyDatePrice TargetRatingAnalyst
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Insmed Incorporated
    $INSM
    12/19/2025$202.00Buy
    Truist
    Elbit Systems Ltd.
    $ESLT
    12/11/2025Equal-Weight
    Morgan Stanley
    Insmed Incorporated
    $INSM
    12/4/2025$263.00Buy
    Rothschild & Co Redburn
    Insmed Incorporated
    $INSM
    10/28/2025$192.00Overweight
    Cantor Fitzgerald
    Insmed Incorporated
    $INSM
    10/20/2025$171.00Overweight
    Wells Fargo
    Elbit Systems Ltd.
    $ESLT
    9/30/2025$520.00Neutral
    Analyst
    More analyst ratings

    $APDN
    $CALT
    $ESLT
    $INSM
    SEC Filings

    View All

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    3/5/26 4:59:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    2/27/26 10:13:31 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form S-1/A filed by Netcapital Inc.

    S-1/A - Netcapital Inc. (0001414767) (Filer)

    2/24/26 4:40:35 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $APDN
    $CALT
    $ESLT
    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Insmed with a new price target

    Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $231.00

    1/28/26 7:17:09 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Insmed with a new price target

    Roth Capital initiated coverage of Insmed with a rating of Buy and set a new price target of $212.00

    1/23/26 8:19:26 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Insmed with a new price target

    Truist resumed coverage of Insmed with a rating of Buy and set a new price target of $202.00

    12/19/25 8:48:21 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,562,328 worth of shares (10,699 units at $146.03) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:16:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 100 shares, decreasing direct ownership by 0.04% to 242,776 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:15:10 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 1,072 shares and received a gift of 972 shares, decreasing direct ownership by 0.44% to 242,876 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/27/26 4:14:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    From the Tarmac to the Stars: Defense Budgets Fueling the Next Aerospace Boom

    CAPE CANAVERAL, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The U.S. Space Force secured a nearly $14 billion boost to its budget in fiscal 2026, bringing its total allocation to approximately $40 billion, more than double its first independent budget of $15 billion in fiscal 2021[1]. The administration has proposed increasing total annual military spending to $1.5 trillion by fiscal 2027, with specific focus on the Golden Dome proliferated space-based defense architecture and proliferated satellite constellations[2]. Companies positioned across aerospace testing, defense manufacturing, and space infrastructure include Starfighters Space (NYSE-A: FJET), AeroVi

    3/6/26 9:00:00 AM ET
    $ACHR
    $AVAV
    $CW
    Aerospace
    Industrials
    Industrial Machinery/Components
    Technology

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence

    3/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Defense Budget Supercycle Nobody Saw Coming

    Issued on behalf of VisionWave Holdings, Inc.NEW YORK, Feb. 25, 2026 /CNW/ -- USA News Group News Commentary -- Global military spending reached a record $2.72 trillion in 2024, marking the steepest annual increase since the Cold War[1]. The Department of Defense has requested $3.0 billion for hypersonic weapons programs in its FY2026 budget, signaling sustained investment in next-generation strike and defense capabilities[2]. Companies positioned across this accelerating defense technology landscape include VisionWave Holdings (NASDAQ:VWAV), Kratos Defense & Security Solutions (NASDAQ:KTOS), Ondas Holdings (NASDAQ:ONDS), Parsons (NYSE:PSN), and Elbit Systems (NASDAQ:ESLT).

    2/25/26 8:50:00 AM ET
    $ESLT
    $KTOS
    $ONDS
    Military/Government/Technical
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $APDN
    $CALT
    $ESLT
    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Financials

    Live finance-specific insights

    View All

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elbit Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 17, 2026

    The Company will host an investor conference with management to discuss 2025 financial resultsThe Company will host a Conference Call to discuss its financial results on March 17, 2026 at 10:00am ETHAIFA, Israel, Feb. 17, 2026 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ:ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it will publish its fourth quarter and full year 2025 financial results on Tuesday, March 17, 2026. Results Conference CallThe Company will host a conference call on March 17, 2026, at 10:00am Eastern Time. On the call, management will review and discuss the results and will be available to answer questions. To participate, please call one of the dial-i

    2/17/26 2:59:00 AM ET
    $ESLT
    Military/Government/Technical
    Industrials

    Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

    BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 19, 2026. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, February 19, 2026, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) an

    2/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $ESLT
    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary